ArticlePloS one2020

Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.

C R Kahlert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.